ArticleFrontiers in immunology2020
Fungal Dysbiosis and Intestinal Inflammation in Children With Beta-Cell Autoimmunity.
Article in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05252728 (Altered Faecal Microbiome and Metabolome in Childhood-onset Type 1 Diabetes, Adult-onset Type 1 Diabetes and Type 2 Diabetes), which is not on this map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Altered Faecal Microbiome and Metabolome in Childhood-onset Type 1 Diabetes, Adult-onset Type 1 Diabetes and Type 2 Diabetes
Who cites it
27 citing papers in PubMed, 48 citations in OpenAlex.
- Trial
- Trial
- Synbiotic Effect of Saccharomyces boulardii and Fructans from Agave salmiana on the Modulation of Intestinal Microbiota in Children Under Antibiotics.Probiotics and antimicrobial proteins · 2026Article
- Intestinal Microbiota in Diabetes-Does the Pathomechanism and Diversity Depend on the Type of Diabetes and Coexisting Metabolic Disorders?Journal of clinical medicine · 2026Review
- Early-Life Gut Microbiota: Education of the Immune System and Links to Autoimmune Diseases.Microorganisms · 2026Review
- Exploring the multifaceted roles of beta-defensins in prediabetes: a detailed review.Frontiers in endocrinology · 2026Review
- Multifaceted effects of the microbiome in pancreatic cancer: from association to modulation.Nature reviews. Gastroenterology & hepatology · 2025Review
- Interplay between fungal infections and autoimmunity: mechanisms and therapeutic perspectives.EMBO molecular medicine · 2025Review
- The Gut Mycobiome for Precision Medicine.Journal of fungi (Basel, Switzerland) · 2025Review
- Gut mycobiome in cardiometabolic disease progression: current evidence and future directions.Frontiers in microbiology · 2025Review
- Gut Inflammation Markers, Diet, and Risk of Islet Autoimmunity in Finnish Children - A Nested Case-Control Study.The Journal of nutrition · 2024Article
- Maternal provisions in type 1 diabetes: Evidence for both protective & pathogenic potential.Frontiers in immunology · 2023Review
- Alterations of bacteriome, mycobiome and metabolome characteristics in PCOS patients with normal/overweight individuals.Journal of ovarian research · 2022Article
- The Human Mycobiome: Colonization, Composition and the Role in Health and Disease.Journal of fungi (Basel, Switzerland) · 2022Review
- Fungal diversity in the gut microbiome of young South African children.BMC microbiology · 2022Article
- Salivary levels of hBDs in children and adolescents with type 1 diabetes mellitus and gingivitis.Clinical oral investigations · 2022Article
- The Intestinal Microbiota May Be a Potential Theranostic Tool for Personalized Medicine.Journal of personalized medicine · 2022Review
- Protective role of butyrate in obesity and diabetes: New insights.Frontiers in nutrition · 2022Review
- Changes in the gut microbiota: a possible factor influencing peripheral blood immune indexes in non-obese diabetic mice.Antonie van Leeuwenhoek · 2021Article
- Modulation of Intestinal ILC3 for the Treatment of Type 1 Diabetes.Frontiers in immunology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although gut bacterial dysbiosis is recognized as a regulator of beta-cell autoimmunity, no data is available on fungal dysbiosis in the children at the risk of type 1 diabetes (T1D). We hypothesized that the co-occurrence of fungal and bacterial dysbiosis contributes to the intestinal inflammation and autoimmune destruction of insulin-producing beta-cells in T1D. Fecal and blood samples were collected from 26 children tested positive for at least one diabetes-associated autoantibody (IAA, GADA, IA-2A or ICA) and matched autoantibody-negative children with HLA-conferred susceptibility to T1D (matched for HLA-DQB1 haplotype, age, gender and early childhood nutrition). Bacterial 16S and fungal ITS2 sequencing, and analyses of the markers of intestinal inflammation, namely fecal human beta-defensin-2 (HBD2), calprotectin and secretory total IgA, were performed. Anti-Saccharomyces cerevisiae antibodies (ASCA) and circulating cytokines, IFNG, IL-17 and IL-22, were studied. After these analyses, the children were followed for development of clinical T1D (median 8 years and 8 months). Nine autoantibody positive children were diagnosed with T1D, whereas none of the autoantibody negative children developed T1D during the follow-up. Fungal dysbiosis, characterized by high abundance of fecal
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.